Literature DB >> 16211273

Effect of bilateral oophorectomy on mammary tumor formation in BRCA1 mutant mice.

Richard Bachelier1, Xiaoling Xu, Cuiling Li, Wenhui Qiao, Priscilla A Furth, Ronald A Lubet, Chu-Xia Deng.   

Abstract

Germline mutations of breast cancer-associated gene 1 (BRCA1) predispose women to breast and ovarian cancer. It was recently shown that bilateral oophorectomy decreases breast cancer incidence in BRCA1 mutation carriers. To model human BRCA1 carriers, our laboratory has previously created mice with a conditional knockout of the full-length BRCA1 gene in the mammary epithelium combined with a heterozygous knockout of the p53 tumor suppressor gene. These mice developed ER-negative mammary tumors and were employed to determine the effects of oophorectomy on tumor formation. Individual knockout mice (BRCA1(Co/Co) MMTV-Crep53+/-), following two complete pregnancies, were either oophorectomized or sham treated. Mice were subsequently examined for the development of palpable mammary tumors until they were 12 months of age. Until 135 days post-oophorectomy (255 days of age), the tumor incidence was similar in both oophorectomized and intact mice, approximately 30%. After this time, the increase in tumor incidence was much lower in the oophorectomized mice, while tumor incidence increased in non-oophorectomized mice. The effects of oophorectomy on mammary development in both control and knockout mice were also examined. Oophorectomized mice with a conditional knockout of full-length BRCA1 in conjunction with a loss of one p53 allele exhibited glandular regression with a reduction in the number of mammary epithelial cells following oophorectomy. This study employed a model that may be relevant for testing agents useful against breast cancer in BRCA1 carriers and a subset of sporadic cancers. The data also show that oophorectomy, if performed significantly prior to the time that tumors arise, appears to be quite effective.

Entities:  

Mesh:

Year:  2005        PMID: 16211273

Source DB:  PubMed          Journal:  Oncol Rep        ISSN: 1021-335X            Impact factor:   4.136


  15 in total

1.  CDDO-methyl ester delays breast cancer development in BRCA1-mutated mice.

Authors:  Eun-Hee Kim; Chuxia Deng; Michael B Sporn; Darlene B Royce; Renee Risingsong; Charlotte R Williams; Karen T Liby
Journal:  Cancer Prev Res (Phila)       Date:  2011-09-20

2.  BRCA1 represses DNA replication initiation through antagonizing estrogen signaling and maintains genome stability in parallel with WEE1-MCM2 signaling during pregnancy.

Authors:  Xiaoling Xu; Eric Chen; Lihua Mo; Lei Zhang; Fangyuan Shao; Kai Miao; Jianlin Liu; Sek Man Su; Monica Valecha; Un In Chan; Hongping Zheng; Mark Chen; Weiping Chen; Qiang Chen; Haiqing Fu; Mirit I Aladjem; Yanzhen He; Chu-Xia Deng
Journal:  Hum Mol Genet       Date:  2019-03-01       Impact factor: 6.150

Review 3.  Genomic instability in breast and ovarian cancers: translation into clinical predictive biomarkers.

Authors:  Marieke A Vollebergh; Jos Jonkers; Sabine C Linn
Journal:  Cell Mol Life Sci       Date:  2011-09-16       Impact factor: 9.261

Review 4.  Assessing estrogen signaling aberrations in breast cancer risk using genetically engineered mouse models.

Authors:  Priscilla A Furth; M Carla Cabrera; Edgar S Díaz-Cruz; Sarah Millman; Rebecca E Nakles
Journal:  Ann N Y Acad Sci       Date:  2011-07       Impact factor: 5.691

Review 5.  BRCA1 deficient mouse models to study pathogenesis and therapy of triple negative breast cancer.

Authors:  Edgar S Diaz-Cruz; Marina C Cabrera; Rebecca Nakles; Beth H Rutstein; Priscilla A Furth
Journal:  Breast Dis       Date:  2010

6.  AKT regulates BRCA1 stability in response to hormone signaling.

Authors:  Andrew C Nelson; Traci R Lyons; Christian D Young; Kirk C Hansen; Steven M Anderson; Jeffrey T Holt
Journal:  Mol Cell Endocrinol       Date:  2010-01-18       Impact factor: 4.102

7.  Mechanism of BRCA1-mediated inhibition of progesterone receptor transcriptional activity.

Authors:  Pragati Katiyar; Yongxian Ma; Anna Riegel; Saijun Fan; Eliot M Rosen
Journal:  Mol Endocrinol       Date:  2009-04-23

8.  Activation of estrogen signaling pathways collaborates with loss of Brca1 to promote development of ERalpha-negative and ERalpha-positive mammary preneoplasia and cancer.

Authors:  L P Jones; M T Tilli; S Assefnia; K Torre; E D Halama; A Parrish; E M Rosen; P A Furth
Journal:  Oncogene       Date:  2007-07-23       Impact factor: 9.867

9.  The PPARγ agonist efatutazone increases the spectrum of well-differentiated mammary cancer subtypes initiated by loss of full-length BRCA1 in association with TP53 haploinsufficiency.

Authors:  Rebecca E Nakles; Bhaskar V S Kallakury; Priscilla A Furth
Journal:  Am J Pathol       Date:  2013-05-08       Impact factor: 4.307

Review 10.  Derailed estrogen signaling and breast cancer: an authentic couple.

Authors:  Bramanandam Manavathi; Oindrilla Dey; Vijay Narsihma Reddy Gajulapalli; Raghavendra Singh Bhatia; Suresh Bugide; Rakesh Kumar
Journal:  Endocr Rev       Date:  2012-09-04       Impact factor: 19.871

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.